Zalicus plummets after dropping lead compound

Zalicus Inc. (NASDAQ:ZLCS) fell $3.39 (72%) to $1.30 on Monday after discontinuing development of its lead compound, Z160, after the N-type calcium channel inhibitor missed the primary endpoint in a p...